- Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro
-
Jae-Sug Lee, Hwa-Jung Choi, Jae-Hyoung Song, Hyun-Jeong Ko, Kyungah Yoon, Jeong-Min Seong
-
Osong Public Health Res Perspect. 2017;8(5):318-324. Published online October 31, 2017
-
DOI: https://doi.org/10.24171/j.phrp.2017.8.5.05
-
-
4,833
View
-
30
Download
-
8
Crossref
-
 Abstract
 PDF
- Objectives
Echovirus 30 is a major cause of meningitis in children and adults. The aim of this study was to investigate whether the antifungal drug itraconazole could exhibit antiviral activity against echovirus 30. MethodsThe cytopathic effect and viral RNA levels were assessed in RD cells as indicators of viral replication. The effects of itraconazole were compared to those of two known antiviral drugs, rupintrivir and pleconaril. The time course and time-of-addition assays were used to approximate the time at which itraconazole exerts its activity in the viral cycle. ResultsItraconazole and rupintrivir demonstrated the greatest potency against echovirus 30, demonstrating concentration-dependent activity, whereas pleconaril showed no antiviral activity. Itraconazole did not directly inactivate echovirus 30 particles or impede viral uptake into RD cells, but did affect the initial stages of echovirus 30 infection through interference with viral replication. ConclusionItraconazole can be considered a lead candidate for the development of antiviral drugs against echovirus 30 that may be used during the early stages of echovirus 30 replication.
-
Citations
Citations to this article as recorded by  - Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances
Chiara Tammaro, Michela Guida, Federico Appetecchia, Mariangela Biava, Sara Consalvi, Giovanna Poce
Pharmaceuticals.2023; 16(2): 203. CrossRef - Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
Leena Abdulaziz, Esraa Elhadi, Ejlal A Abdallah, Fadlalbaseer A Alnoor, Bashir A Yousef
Journal of Experimental Pharmacology.2022; Volume 14: 97. CrossRef - Identification of novel Ebola virus inhibitors using biologically contained virus
Bert Vanmechelen, Joren Stroobants, Winston Chiu, Joost Schepers, Arnaud Marchand, Patrick Chaltin, Kurt Vermeire, Piet Maes
Antiviral Research.2022; 200: 105294. CrossRef - The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication
Lucca Policastro, Isabela Dolci, Andre Godoy, José Silva Júnior, Uriel Ruiz, Igor Santos, Ana Jardim, Kirandeep Samby, Jeremy Burrows, Timothy Wells, Laura Gil, Glaucius Oliva, Rafaela Fernandes
Viruses.2022; 14(7): 1351. CrossRef - Itraconazole and Posaconazole from Antifungal to Antiviral Drugs
Falah Hasan Obayes AL-Khikani
Biomedical and Biotechnology Research Journal (BBR.2022; 6(2): 164. CrossRef - Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle
Eric Rhoden, Terry Fei Fan Ng, Ray Campagnoli, W. Allan Nix, Jennifer Konopka-Anstadt, Rangaraj Selvarangan, Laurence Briesach, M. Steven Oberste, William C. Weldon
Antimicrobial Agents and Chemotherapy.2020;[Epub] CrossRef - Potential antiviral properties of antifungal drugs
FalahH.O Al-Khikani, HudaA.S Almosawey, YounusJ Abdullah, AtyafA Al-Asadi, RaghdahM Hameed, NoorF Hasan, MohanadK.M Al-Ibraheemi
Journal of the Egyptian Women's Dermatologic Socie.2020; 17(3): 185. CrossRef - Repurposing approach identifies new treatment options for invasive fungal disease
Isis Regina Grenier Capoci, Daniella Renata Faria, Karina Mayumi Sakita, Franciele Abigail Vilugron Rodrigues-Vendramini, Patricia de Souza Bonfim-Mendonça, Tania Cristina Alexandrino Becker, Érika Seki Kioshima, Terezinha Inez Estivalet Svidzinski, Berna
Bioorganic Chemistry.2019; 84: 87. CrossRef
|
